Ma J, Tai S, Leung LWS (2007) Ketamine-induced gating deficit of hippocampal auditory evoked potentials in rats is alleviated by medial septum inactivation and antipsychotic drugs. Neuroscience 2007 Abstracts 498.12/GG19. Society for Neuroscience, San Diego, CA.
Summary: Gating of sensory responses is impaired in schizophrenic patients and animal models of schizophrenia. Ketamine, an N-methyl-D-aspartate receptor antagonist, is known to induce schizophrenic-like symptoms in humans. In this study, we investigated some conditions underlying ketamine’s effect on the gating of auditory responses in the hippocampus of freely moving rats. Gating was measured by the ratio of the second-click response (P2) to the first-click response (P1), or P2/P1, with P1 and P2 measured as peak amplitudes. Ketamine (1, 3 or 6 mg/kg s.c.) dose- dependently increased P2/P1 ratio as compared to saline (s.c.). P2/P1 ratio in saline injected rats was 0.48 + 0.05 and was 0.73 + 0.17 in ketamine (3mg/kg) treated rats. Pre-inactivation of the medial septum with GABAA receptor agonist muscimol (0.25 μg/0.6 μL) or systemic administration of antipsychotic drugs, including chlorpromazine (5 mg/kg i.p.), haloperidol (1 mg/kg i.p.) or clozapine (7.5 mg/kg i.p.), decreased P2/P1 to values comparable to normal rats without drug injection. Infusion of muscimol in the medial septum or injection of antipsychotic drug alone did not affect the P2/P1 ratio. However, rats with selective lesion of the septohippocampal cholinergic neurons (by 192-IgG saporin) showed significant higher P2/P1 (0.86 + 0.10) than that of sham lesioned rats (0.26 + 0.07), but ketamine’s effect in increasing P2/P1 ratio was preserved. It is suggested that the septohippocampal cholinergic inputs participate in normal auditory gating in the hippocampus whereas the entire medial septum mediates ketamine-induced deficit of hippocampal auditory gating. In addition, the effectiveness of various antipsychotic drugs in antagonizing ketamine-induced impairment of auditory gating confirms the validity of this animal model of schizophrenia. (Supported by NSERC grant and CIHR grant 15685).
Related Products: 192-IgG-SAP (Cat. #IT-01)